All In Biotech

BLA 103353 · Amgen

Neupogen

Filgrastim · Leukocyte Growth Factor

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1991

Feb 20, 1991

Approved uses

6

Original approval plus efficacy supplements

Registered trials

1,650

302 Phase 3, 127 recruiting

FAERS reports

37,808

33,318 serious, 8,531 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 23, 2026.

NEUPOGEN is a leukocyte growth factor indicated to Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) Reduce the incidence and duration of sequelae of severe neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia ( 1.5 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy NEUPOGEN is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1) ] . 1.2 Patients with Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment...

Mechanism: Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation, differentiation commitment, and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is produced by monocytes, fibroblasts, and endothelial cells. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation, differentiation, and selected end-cell functions (including enhanced phagocytic ability, priming of the cellular metabolism...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 30, 2015 Supplement 5183 · Efficacy OrphanLabelLetter
  • Apr 2, 1998 Supplement 1036 · Efficacy LabelLetter
  • Dec 28, 1995 Supplement 1027 · Efficacy
  • Dec 19, 1994 Supplement 1007 · Efficacy · priority review
  • Jun 15, 1994 Supplement 1009 · Efficacy
  • Feb 20, 1991 Original approval · Type 1 - New Molecular Entity · priority review Review
4 products under this application
  • NEUPOGEN · FILGRASTIM 300MGC/0.5ML · SYRINGE, · Prescription
  • NEUPOGEN · FILGRASTIM 300MCG/1ML · VIAL, · Prescription
  • NEUPOGEN · FILGRASTIM 480MCG/0.8ML · SYRINGE, · Prescription
  • NEUPOGEN · FILGRASTIM 480MCG/1.6ML · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Filgrastim" as an intervention, any sponsor and status, largest first.

All 1,650 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia4,533
  • neutropenia3,559
  • off label use3,198
  • pyrexia2,929
  • diarrhoea2,297
  • death2,288
  • nausea2,067
  • thrombocytopenia2,022
  • pneumonia1,923
  • fatigue1,864
  • anaemia1,832
  • sepsis1,511

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004422
2005432
2006483
2007701
2008855
2009826
2010895
20111,381
20121,832
20131,169
20141,372
20151,609
20161,752
20171,717
20182,275
20192,130
20202,517
20213,218
20222,982
20232,710
20242,834
20252,360
20261,333

Recalls

2 FDA enforcement reports for this application.

  • Feb 27, 2025 · Class II · Ongoing

    Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.

  • Feb 27, 2025 · Class II · Ongoing

    Stability data does not support expiry: the products have the potential to be out of specification at the time of expiry of 36-months.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Neupogen (Filgrastim)

2024 spending

$7.2M

Beneficiaries

1,038

2,908 claims

Per beneficiary

$6,945

$599.02 per unit

View as table
YearSpending
2020$23,948,971
2021$14,822,399
2022$11,191,804
2023$9,654,765
2024$7,208,750

Part B: Neupogen (Filgrastim) · HCPCS J1442

2024 spending

$9.9M

Beneficiaries

4,056

21,259 claims

Per beneficiary

$2,443

2024 ASP limit $0.99 per unit

View as table
YearSpending
2020$21,674,065
2021$16,004,308
2022$14,520,473
2023$12,277,218
2024$9,906,867

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 763 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.